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Our hypothesis is that leptin release is controlled neurohormon-
ally. Conscious, male rats bearing indwelling, external, jugular
catheters were injected with the test drug or 0.9% NaCl (saline),
and blood samples were drawn thereafter to measure plasma
leptin. Anesthesia decreased plasma leptin concentrations within
10 min to a minimum at 120 min, followed by a rebound at 360 min.
Administration (i.v.) of lipopolysaccharide (LPS) increased plasma
leptin to almost twice baseline by 120 min, and it remained on a
plateau for 360 min, accompanied by increased adipocyte leptin
mRNA. Anesthesia largely blunted the LPS-induced leptin release at
120 min. Isoproterenol (-adrenergic agonist) failed to alter plasma
leptin but reduced LPS-induced leptin release significantly. Pro-
pranolol (-receptor antagonist) produced a significant increase in
plasma leptin but had no effect on the response to LPS. Phentol-
amine (-adrenergic receptor blocker) not only increased plasma
leptin (P < 0.001), but also augmented the LPS-induced increase
(P < 0.001). -Bromoergocryptine (dopaminergic-2 receptor ago-
nist) decreased plasma leptin (P < 0.01) and blunted the LPS-
induced rise in plasma leptin release (P < 0.001). We conclude that
leptin is at least in part controlled neurally because anesthesia
decreased plasma leptin and blocked its response to LPS. The
findings that phentolamine and propranolol increased plasma
leptin concentrations suggest that leptin release is inhibited by the
sympathetic nervous system mediated principally by -adrenergic
receptors because phentolamine, but not propranolol, augmented
the response to LPS. Because -bromoergocryptine decreased
basal and LPS-induced leptin release, dopaminergic neurons may
inhibit basal and LPS-induced leptin release by suppression of
release of prolactin from the adenohypophysis.
plasma leptin  ketamine  isoproterenol  propanolol  phentolamine
The close interrelationships among the immune, endocrine,and nervous systems allow the organism to respond as a
whole to different types of stress and changes in the environ-
ment. Rather than acting independently, these systems are
closely interrelated through their messenger molecules: cyto-
kines, hormones, neurotransmitters, neuropeptides, and nitric
oxide. Thus, a complex network allows the organism to respond
to noxious stimuli and changes in the environment to preserve
homeostasis (1).
In inflammatory stress induced by peripheral or central ad-
ministration of lipopolysaccharide (LPS) in rodents, there are a
number of changes in the immune system such as: stimulation of
release of acute phase proteins, induction of nitric oxide synthase
activity and synthesis, and increased release of cytokines (2–7).
Proinflammatory cytokines, such as tumor necrosis factor  and
IL-1, released from immune cells reach the central nervous
system (CNS) and increase release of corticotrophin-releasing
hormone that activates the pituitary–adrenal axis (8). LPS also
alters the release of other pituitary hormones in rats, increasing
prolactin release and decreasing growth hormone, thyroid-
stimulating hormone, and luteinizing hormone release (5).
There are a variety of other changes in the CNS caused by LPS
as well, many of which probably are mediated by LPS-induced
cytokine release, such as alterations of central and peripheral
catecholamine levels (9, 10) and alteration of neurotransmitter
release in different areas of the brain (11). These result in
induction of fever, loss of appetite, libido, and somnolence, and
many metabolic changes.
Leptin is a cytokine (12–15), and, like other proinflammatory
cytokines, such as tumor necrosis factor , IL-1, and IL-6, leptin
also is secreted in response to the inflammatory stress induced
by LPS (1, 16). In previous research, we have determined that i.v.
injection of LPS in conscious, freely moving rats bearing in-
dwelling, jugular catheters increased plasma leptin concentra-
tions 100% over baseline concentrations within 2 h (16). Similar
results also were found in experiments in mice (17). Recent
research in humans showed that plasma leptin levels were
increased in survivors of acute sepsis (18), and it was shown in
another in vivo paradigm in mice that leptin exerted a protective
effect on tumor necrosis factor -induced sepsis (19), suggesting
that leptin might be an antistress cytokine.
Plasma leptin concentrations have a circadian rhythm, with
values peaking in the middle of the night in both humans (20)
and rats (21). There is also an ultradian rhythm of plasma leptin
in humans (20). These studies suggest that leptin release is
controlled by the CNS. That anesthetization and surgical stress
significantly decreased plasma leptin concentration in male rats
(22) led us to hypothesize that stress-induced alterations in leptin
release are also under the control of the CNS. Therefore, we
decided to evaluate the role of anesthesia in a different model of
stress, namely, the inflammatory stress induced by LPS. Because
anesthesia alters the activity of the sympathetic nervous system,
we studied the effect of isoproterenol (-adrenergic agonist),
propranolol (-adrenergic antagonist), -bromoergocryptine
(a dopamine 2 agonist), and phentolamine (-adrenergic
antagonist) alone or in the presence of LPS on plasma leptin
concentrations.
Materials and Methods
Animals. Adult male rats (350–400 g) of the Holtzman strain
(Harlan–Sprague–Dawley) were used. Upon arrival, the animals
were allowed to acclimate for 2 weeks in a room with controlled
temperature (23–25°C) and lighting (lights on from 7 a.m. to
7 p.m.). A standard pellet diet and tap water were available ad
libitum. Procedures involving animals were approved by the
Pennington Biomedical Research Center–Institutional Animal
Care and Use Committee.
Drugs. All of the drugs were purchased from Sigma with the
exception of the anesthetic (ketamineacepromazinexylazine),
which was provided by the Division of Comparative Biology at
Pennington Biomedical Research Center. The drugs were
freshly prepared on the day of the experiment and dissolved in
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(0.15 M NaCl) saline with the exception of -bromoergocryp-
tine, which was dissolved in ethanol (ETOH) at a concentration
of 16 mgml, and, thereafter, it was diluted in saline to the final
concentration. The final concentration of ETOH was 18.75%.
-Bromoergocryptine (5 mgkg) was injected i.v. at a volume of
0.5 ml. LPS (0127:B8) (0.15 mgkg) was also injected i.v. at a
volume of 0.5 ml. The other drugs, isoproterenol, propranolol,
and phentolamine, were injected i.p. at a dose of 10 mgkg
dissolved at a volume of 0.4 ml of saline. Phentolamine was
sonicated until complete dissolution in an ultrasonic device
(Bransonic 2210; Danbury, CT).
Repeated Blood Sampling. One day before blood sampling, a
silastic catheter was introduced into the right external jugular
vein and advanced to the right atrium according to the technique
of Harms and Ojeda (23) by using i.p. ketamineaceproma-
zinexylazine anesthesia (90  2  6 mgml, respectively), 0.1
ml100 g body weight.
After the operation, the rats were housed singly in cages
overnight in the experimental room. One hour before the
experiment, polyethylene tubing filled with 0.9% NaCl (saline)
containing 500 unitsml heparin was connected to the jugular
catheter, and 0.5 ml of 500 unitsml heparin was injected.
Immediately after collection of the initial (0.6 ml) blood sample
(time  15 min), the test substance dissolved in 0.5 ml of saline
or the saline diluent was injected i.v. over a period of 30 sec.
Fifteen minutes later (time 0), LPS or saline was injected.
Thereafter, subsequent samples were withdrawn at 15, 30, 120,
240, and 360 min. Each time, the volume of blood withdrawn was
replaced by an equal volume of saline containing 50 unitsml
heparin. Blood was centrifuged (650  g) during 15 min, and
plasma was stored at 70°C until determination of leptin.
Plasma Leptin Determination. Leptin was measured by RIA with
rat leptin kits purchased from Linco Research Immunoassay (St.
Charles, MO). The intraassay and interassay coefficients of
variation were 3.7% and 4.2%, respectively. The curve was linear
between 1 and 20 ngml.
Leptin mRNA Analysis. Total RNA was isolated from epididymal
fat pads by using RNAzol B, followed by precipitation with
isopropanol and ethanol washes according to the manufacturer’s
instructions (Tel-Test, Friendswood, TX). Protection assays
were performed by the protocol as described (24), with some
modifications. A 342-bp fragment of rat leptin cDNA cloned into
PCRII vector was kindly provided by Ruth B. S. Harris (Loui-
siana State University). The construct was linearized with BsaI
and used to generate a 32P-labeled antisense cRNA by using a
riboprobe kit (Promega) with T7 RNA polymerase. The total
RNA (12 g) was hybridized with 250,000 cpm of gel-purified
32P-labeled antisense probe in 20 l of buffer containing 80%
deionized formamide, 40 mm piperazine-N-N-bis (2-ethanesul-
fonic acid) (pH 6.4), 0.4 M NaCl, and 1 mM EDTA for 16 h at
45°C. All samples were hybridized to 250,000 cpm of 32P-labeled
labeled cyclophilin cRNA to normalize the leptin mRNA values.
After hybridization, the samples were digested with 5 units of
RNase I (Promega) in the presence of RNase digestion buffer
containing 10 mM TrisHCl (pH 7.5), 5 mM EDTA, and 200 mM
sodium acetate at 37° for 1 h. The digestion reaction was
terminated by the addition of 3 l of 20% SDS and 10 g
yeast-transfer RNA. Protected hybrids were precipitated with
2–3 vol of ethanol, denatured, and electrophoresed on a 5%
polyacrylamide gel containing 7 M urea. The integrated optical
density of bands of the autoradiographic exposures from each gel
were quantified by scanning densitometry.
Statistical Analysis. Statistical differences between two means
were calculated by Student’s t test when the data passed the
normality and equal variance test. When the data did not pass the
normality and equal variance test, a nonparametric test was
performed, namely, the Mann–Whitney U test. The data are
expressed as percentage of the initial value, where the initial
concentration of plasma leptin was considered 100%. In the
isoproterenol experiments, the Delta Minimum was calculated,
taking the maximum difference obtained below the baseline
leptin concentration. The area under the curve and all of the
statistical analysis were performed with GRAPH PAD PRISM 3.
Results
Effect of Anesthesia on LPS-Induced Leptin Release. Saline (0.4 ml)
or ketamineacepromazinexylazine (90  2  6 mgml,
respectively; 0.1 ml100 g body weight), the same dose used in
our previous research (22), was injected i.p. at15 min. By time
0, the anesthetic decreased leptin concentrations and there was
a very significant difference between the anesthetic-treated rats
and the control group (P  0.001) (Fig. 1). In this and the
following experiments, a second i.v. control injection of saline or
LPS (0.15 mgkg) was administered at time 0 (Fig. 2). After time
0, the anesthetic further decreased leptin concentrations that
reached their minimum at 120 min (P  0.05) vs. saline-treated
rats. There was a very significant, negative linear regression
between15 min and 120 min in the anesthetic-treated rats (P
0.003 and r 0.98; data not shown). Thereafter, between 120 and
360 min, there was a rebound in plasma leptin concentration that
exceeded the values in the saline-treated rats at 360 min (P 
0.05), nearly a 2-fold increase over the starting value. During this
time, 120–360 min, there was a positive linear regression of
plasma leptin with time (P  0.01, r  0.999) (data not shown)
in the anesthetized rats.
After LPS injection, plasma leptin concentrations gradually
increased, reaching a significant difference at 30 min (P 0.01),
plateaued from 120 to 240 min, and then climbed to a maximum,
more than 2-fold increase at 360 min (P 0.001). In the presence
of LPS, ketamine partially blocked the LPS-induced leptin
release by 65% at 120 min (Fig. 2) [P  0.01 vs. (saline 
LPS)-treated rats; P  0.05 vs. ketamine alone]. Thereafter,
there was a rebound in plasma leptin concentration in ketamine
plus LPS-injected rats that rose to a peak at 360 min of almost
300% over its initial value. The largest differences among the
four groups were obtained at 120 min as shown in Fig. 2.
Fig. 1. The effect of ketamineacepromazinexylazine anesthesia (90  2
 6 mgml, respectively; 0.1 ml100 g body weight) on leptin release 15 min
after injection. The number of animals (n)  13 in both groups. In this and
subsequent figures, bars or symbols represent the mean response at each time
point. The vertical line above or below the bars or symbols represents 1 SEM.
***, P  0.001 vs. saline.







Effect of Isoproterenol (-Adrenergic Agonist) on LPS-Induced Leptin
Release. Isoproterenol, injected at the same dose (10 mgkg)
used to block LPS-induced tumor necrosis factor  release (25),
or saline was injected i.p. at 30 min. At time 0, there were no
significant differences in plasma leptin between the isoprotere-
nol- and saline-treated groups (data not shown). Saline-injected
rats presented no significant differences from the isoproterenol-
treated group at any time point; however, calculation of the
Delta Minimum between the saline- and isoproterenol-treated
groups revealed that isoproterenol significantly decreased
plasma leptin concentrations (P  0.05; data not shown). LPS
was injected at time 0, resulting in a similar pattern of plasma
leptin as that in Fig. 2 (Fig. 3). Isoproterenol partially decreased
LPS-induced plasma leptin concentration at 120 min by 40%
(P 0.05; Fig. 3). The area under the curve was calculated between
0 and 120 min, showing that isoproterenol decreased LPS-induced
leptin release (P  0.01 vs. saline  LPS; data not shown).
Effect of Propranolol on LPS-Induced Leptin Release. Saline or
propranolol (10 mgkg) at the same dose used previously (25)
was injected at 15 min. There were no significant differences
between15 and 0 min between saline- and propranolol-treated
rats (data not shown). Thereafter, in the presence of propran-
olol, plasma leptin concentrations were not significantly higher
at 240 and 360 min than in the saline-treated rats (Fig. 4).
Propranolol had no effect on LPS-induced leptin release (Fig. 4).
Effect of Phentolamine (-Adrenergic Antagonist) on LPS-Induced
Leptin Release. Saline or phentolamine (10 mgkg) at the same
dose used in previous studies (25) was injected i.p. at 15 min.
Phentolamine alone produced a highly significant increase of
20% (P  0.01 vs. saline) in plasma leptin concentration within
15 min (Fig. 5). Thereafter, phentolamine alone increased
plasma leptin concentrations at 120 min that rose further at 240
min (P  0.01 and P  0.001 vs. saline, respectively; Fig. 6). In
the presence of LPS, phentolamine increased plasma leptin
concentrations above those detected in the saline LPS-treated
rats between 120 and 360 min (P 0.01 at 120 min and P 0.05
at 240 and 360 min vs. saline  LPS; Fig. 6).
Effect of -Bromoergocryptine on LPS-Induced Leptin Release. Saline
or -bromocryptine (5 mgkg) at the same dose used previously
(25) was injected i.v. at 15 min. Between 15 and 0 min,
-bromoergocryptine alone decreased plasma leptin highly sig-
nificantly by 18% (P  0.01 vs. saline; Fig. 7) as reported (25).
Thereafter, plasma leptin concentration in the -bromoergo-
cryptine-treated rats remained lower than the saline-treated rats
at 30 min (P  0.05 vs. saline; Fig. 8). Thereafter, plasma leptin
concentrations gradually increased in the -bromoergocryptine-
injected animals, but the values were not significantly greater
than the initial concentrations. In contrast, values in the saline-
injected rats declined progressively and significantly after 30 min
to reach a minimum at 360 min. This resulted in significant
increases in plasma leptin in the bromocryptine- vs. saline-
injected rats (P  0.01 at every time point between 120 and 360
min; Fig. 8). In the presence of LPS, -bromoergocryptine
decreased LPS-induced leptin release between 0 and 120 min
(P  0.01 at 15 min, P  0.05 at 30 min, and P  0.001 at 120
min vs. saline  LPS-treated rats) (Fig. 8).
Effect of LPS on Leptin mRNA in Epididymal Fat Pads. LPS increased
leptin mRNA by 2.3-fold (P  0.05 vs. saline; Fig. 9).
Discussion
That plasma leptin concentration declined gradually in anesthe-
tized male rats during surgery led us to hypothesize that leptin
secretion was under neural control (22). To assess the neural
control of leptin, we used another type of stress, namely, the
inflammatory stress induced by LPS that is known to increase
Fig. 2. The effect of ketamineacepromazinexylazine anesthesia (90  2
 6 mgml, respectively; 0.1 ml100 g body weight) on leptin release. The
number of animals (n)  7 in the saline-treated and anesthetized groups;
n  6 in the saline  LPS-injected rats and in the anesthetic  LPS-treated
group. a, P 0.05 vs. saline; aa, P 0.01 vs. saline; aaa, P 0.001 vs. saline; b,
P  0.05 vs. ketamine alone; c, P  0.05 vs. ketamine  LPS; cc, P  0.01 vs.
ketamine  LPS.
Fig. 3. The effect of 10 mgkg i.p. isoproterenol (Iso) (agonist -adrenergic)
on leptin release. n 8 in the saline-treated rats and in the Iso-injected group;
n 7 in the saline LPS treated-animals and in the Iso LPS-injected rats. aa,
P  0.01 vs. saline; aaa, P  0.001 vs. saline; b, P  0.05 vs. Iso alone (25); bb,
P  0.01 vs. Iso alone; c, P  0.05 vs. Iso  LPS.
Fig. 4. The effect of 10 mgkg propranolol (-adrenergic antagonist) on
leptin release. The number of animals (n) 8 in the saline-injected group, n
10 in the propranolol-treated animals, n  9 in the saline  propranolol-
injected animals, and n 13 in the propranolol LPS-treated rats. *, P 0.05
vs. saline.
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leptin release (16). Furthermore, it was shown that LPS in-
creased catecholamine levels in the CNS (9, 11) and in the
periphery (10) and also activated the hypothalamic–pituitary–
adrenal axis (5, 6). Therefore, we considered the present para-
digm as a suitable model to assess the neural control of leptin.
Our previous results had shown that LPS evoked a rapid and
long-lasting increase in plasma leptin concentrations, with the
first increase obtained within 10 min and a plateau existing from
2 to 6 h. The current results show that at 6 h there was a highly
significant increase in leptin mRNA in epididymal fat pads
induced by LPS. The early release of leptin within 10 min could
not have occurred by new synthesis of leptin and, instead, must
be caused by release of stored leptin that has been found in
pinocytotic vesicles in adipocytes (26). Therefore, presumably,
LPS acts on its receptors within the brain or receptors on afferent
neurons, such as vagal afferents, to activate neural or hormonal
mechanisms that evoke exocytosis of leptin-containing vesicles,
which accounts for the initial elevation of plasma leptin. This is
followed by induction of leptin mRNA, which stimulates leptin
synthesis, contributing to the release that occurs later along with
that of preformed leptin.
As in our previous results with placement of jugular catheters
in anesthetized rats (22), plasma leptin decreased in the current
experiments. Moreover, anesthesia also decreased LPS-induced
plasma leptin release in the same period, providing further
support for our concept that leptin is under neural control.
Surprisingly, ketamine anesthesia either alone or in the presence
of LPS provoked a rebound in plasma leptin levels after 120 min
that reached concentrations similar to or even greater than those
present in the LPS-treated rats. We hypothesize that this re-
bound may be caused by decreased negative feedback of the
depressed plasma leptin concentrations during anesthesia,
which, at the termination of anesthesia, act centrally to stimulate
leptin release.
To understand further the possible role of the sympathetic
nervous system in LPS-induced leptin release, we studied the
effects of - and -adrenergic agonists and antagonists on the
response to LPS. Injection of the -adrenergic agonist, isopro-
terenol, slightly but significantly decreased plasma leptin con-
centrations and, in the presence of LPS, largely blunted the
LPS-induced increase in plasma leptin concentrations. Recently,
it has been shown that there is noradrenergic innervation not
only of brown but also of white fat (27). That propranolol
Fig. 5. The effect of 10 mgkg i.p. phentolamine (Phent) (-adrenergic antag-
onist) on leptin release 10 min after injection. n 17 in the saline-injected group
and n 11 in the phentolamine-treated group; **, P 0.01 vs. saline.
Fig. 6. The effect of 10-mgkg i.p. phentolamine (Phent) (-adrenergic
antagonist) on leptin release. The number of animals (n)  7 in the saline-
injected group, n  5 in the Phent-treated animals, n  10 in the saline 
LPS-injected animals, and n 6 in the Phent LPS-treated rats. a, P 0.05 vs.
saline; aa, P 0.01 vs. saline; aaa, P 0.001 vs. saline; bbb, P 0.001 vs. Phent
alone; c, P 0.05 vs. saline LPS; cc, P 0.01 vs. saline LPS. Standard error
plotted below the mean is represented by a thin line; those above the mean
are represented by thick lines.
Fig. 7. The effect of 5 mgkg i.v. -bromoergocryptine (Bromo) (dopami-
nergic-2 agonist) on leptin release. The values are expressed as a percentage
of the initial values and were obtained 15 min after i.p. injection of saline or
Bromo. The number of animals (n) 13 in both groups. **, P 0.01 vs. saline.
Fig. 8. The effect of 5 mgkg i.v. bromocryptine (Bromo) (dopaminergic-2
agonist) on leptin release. The number of animals (n) 7 in the saline-treated
animals and the Bromo-injected group; n 6 in the saline LPS-treated rats
and in the Bromo LPS-injected animals. a, P 0.05 vs. saline; aa, P 0.01 vs.
saline; aaa, P  0.001 vs. saline; bb, P  0.01 vs. Bromo alone; bbb, P  0.001
vs. Bromo alone; c, P 0.05 vs. Bromo LPS; cc, P 0.01 vs. Bromo LPS; ccc,
P  0.001 vs. Bromo  LPS.







increased baseline concentrations of plasma leptin is consistent
with the hypothesis that there is -adrenergic inhibitory tone
depressing leptin release during resting conditions. However, in
the presence of LPS, propranolol slightly but not significantly
decreased LPS-induced leptin release, suggesting that the inhib-
itory  tone under resting conditions was not present after
injection of LPS. Therefore, our data suggest that either circu-
lating epinephrine andor norepinephrine or norepinephrine
released from noradrenergic terminals may inhibit leptin release
by acting on -adrenergic receptors present on cell membranes
of the adipocytes (28).
Phentolamine, the -adrenergic antagonist, induced a rapid
and highly significant increase in plasma leptin either alone or in
the presence of LPS, suggesting that there is a strong inhibitory
tone acting through the -adrenergic receptors to inhibit not
only basal but LPS-stimulated leptin release.
Recently, we found that prolactin stimulated leptin release
and that -bromoergocryptine, a dopaminergic-2 receptor ago-
nist that inhibits prolactin release from the anterior pituitary
gland, decreased plasma leptin concentrations (21), results that
were obtained independently by Gualillo et al. (29). Moreover,
we have shown previously that LPS increased prolactin release
(5) in a similar experimental paradigm as that used here. Thus,
it is likely that LPS-induced prolactin release increases leptin
release by activation of prolactin receptors on adipocytes (30).
Therefore, we studied the effect of -bromoergocryptine, an
inhibitor of prolactin release, alone or in the presence of LPS. As
in the case of anesthesia, -bromoergocryptine alone or in the
presence of LPS decreased plasma leptin concentrations ini-
tially, but this decrease was followed by a later rebound of a lesser
extent than that observed in the ketamine experiments. The
rebound in both cases may be related to the initial lowering of
plasma leptin, reducing its negative feedback. Then, as the drug
or anesthesia dissipates, an increase in leptin release follows,
leading to the rebound in plasma levels, which presumably is
caused by increased prolactin release.
The decline in leptin in the bromocryptine-injected animals
was much less than in the anesthetized animals, and the rebound
was also less, perhaps because the lesser decrease in plasma
leptin compared with that of anesthetized rats resulted in a lesser
negative feedback of leptin in these animals.
We hypothesize that LPS acts on the CNS to inhibit the
secretion of dopamine, removing the inhibition exerted by
tuberoinfundibullar dopaminergic neurons on the secretion of
prolactin (PRL) (see summary diagram, Fig. 10). Therefore, the
secretion of PRL is increased from the lactotropes. Thereafter,
PRL circulates to the adipose tissue and, acting on its receptors
(PRLr) on the adipocytes, increases the release of leptin that is
stored in pinocytotic vesicles in the cytoplasma adjacent to the
cell membrane. The sympathetic nervous system exerts a tonic
inhibitory effect on leptin release—mediated predominantly by
-adrenergic and, to a lesser extent, by -adrenergic receptors—
that is still present and may be augmented by LPS.
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Fig. 9. (A) Representative autoradiogram showing the detection of leptin
(307 bases) mRNA expressed in total fat RNA (12 g) from control (lanes 2–4)
and LPS-treated rats (lanes 5–7) and digested cyclophilin (132 bases; lanes 2–7).
Lane 1 illustrates the undigested, full-length RNA probes for leptin (376 bases)
and cyclophilin (244 bases). In lane 8, where no hybridization is seen, 12 g of
yeast tRNA was used. (B) Composite drawings showing the densitometric
quantitation of the bands from two blots corresponding to the fat leptin
mRNA isolated from control and LPS (*, P  0.05 vs. saline).
Fig. 10. For description, see Discussion. Opened arrows indicate inhibition,
and solid arrows indicate stimulation. DAn, tuberoinfundibullar dopaminer-
gic neurons; DA, dopamine; ME, median eminence; PV, portal vessels; L,
lactotropes; AP, anterior pituitary; PRL, prolactin; PRLr, PRL receptors; D2r, DA2
receptors; Lm, leptin mRNA; LV, leptin vesicles; A, adipocyte; E, epinephrine;
NE, norepinephrine; A-r, -adrenergic receptors; A-r, -adrenergic recep-
tors; AM, adrenal medulla; S, sympathetic.
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